<DOC>
	<DOCNO>NCT02834559</DOCNO>
	<brief_summary>This study investigate effectiveness simple treatment prevent proliferative vitreoretinopathy ( PVR ) . Intraoperative intravitreal 5-fluorouracil ( 5-FU ) low molecular weight heparin ( LMWH ) use prophylactic therapy high-risk patient primary rhegmatogenous retinal detachment ( RRD ) . Our major motivation reduce incidence PVR group receive trial drug .</brief_summary>
	<brief_title>Prophylactic Intravitreal 5-Fluorouracil Heparin Prevent PVR High-risk Patients With Retinal Detachment .</brief_title>
	<detailed_description>Proliferative vitreoretinopathy ( PVR ) common cause postoperative failure vitreoretinal surgery primary RRD . There standard-therapy prevent PVR . Several attempt use chemotherapeutic agent undertaken prevent proliferation-process , none introduce routine clinical practice . Until recently , challenge identify patient high risk postoperative PVR formation . This especially important , trial treatment trial drug restrict patient high risk PVR . Patients assign follow treatment arm ( 1:1 ) : ( A ) Intraoperative adjuvant application 5-fluorouracil ( 5-FU ) low molecular weight heparin ( LMWH ) via intraocular infusion routine par plana vitrectomy ( PPV ) high-risk patient proliferative vitreoretinopathy ( PVR ) primary rhegmatogenous retinal detachment ( RRD ) . Versus : ( B ) Routinely use intraocular infusion balance salt solution ( BSS ) routine PPV .</detailed_description>
	<mesh_term>Retinal Detachment</mesh_term>
	<mesh_term>Dissociative Disorders</mesh_term>
	<mesh_term>Vitreoretinopathy , Proliferative</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . Primary rhegmatogenous retinal detachment ( &lt; 4 week ) study eye 2 . Scheduled par plana vitrectomy retinal detachment repair without combine cataract surgery study eye 3 . Elevated protein level anterior chamber fluid ( laserflare value ≥ 15.0 pc/ms ) study eye 4 . Female male patient ≥ 18 year age 5 . Written inform consent 1 . Retinal detachment last &gt; 4 week study eye 2 . Traumatic retinal detachment study eye 3 . Giant retinal tear study eye ( size &gt; 3 clock hour ) 4 . Visual preexisting PVR grade C study eye 5 . Retinal dystrophy study eye 6 . Scheduled combined par plana vitrectomy cataract surgery retinal detachment repair study eye 7 . Chronic inflammatory condition study eye 8 . Active retinal vascular disease study eye 9 . Proliferative diabetic retinopathy study eye 10 . Manifest uveitis study eye 11 . Endophthalmitis study eye 12 . Perforating nonperforating trauma study eye 13 . Malignant intraocular tumor study eye 14 . Aphakia study eye 15 . Uncontrolled glaucoma ocular hypertension study eye ( intraocular pressure ≥ 30 mmHg despite IOP lower therapy ) 16 . Previous intraocular surgery except uncomplicated cataract surgery posterior chamber lens implantation study eye 17 . Cataract surgery study eye ≤ 3 month ago 18 . Previous retinal procedure ( laserpexy , cryopexy , intravitreal gasinjection , antiVEGF corticosteroidinjection ) study eye ≤ 6 month 19 . Other uncontrolled ophthalmologic disorder 20 . Single eye patient ( BCVA fellow eye &gt; 1.0 log MAR , &lt; 0.1 decimal , &lt; 1/10 tenth , &lt; 6/60 Snellen fraction [ ] ) 21 . Evidence history alcohol , medication drug dependency within last 12 month . 22 . Evidence history ( within last 12 month ) neurotic personality , psychiatric illness require require treatment , epilepsy suicide risk . 23 . Systemic disorder compatible adjuvant application 5FU LMWH via intraocular infusion , compatible local general anesthesia 24 . Any therapy immunosuppressant chemotherapy ≤ 3 month trial period 25 . Participation another trial IMPs device parallel , less 3 month screen , previous participation trial . 26 . Known suspect able comply protocol . 27 . Inability understand rationale trial study aim 28 . Any dependency patient Investigator trial site , e.g . employee direct involvement propose trial trial direction Investigator trial site , well family member employee Investigator . 29 . Positive urine pregnancy test , pregnancy breastfeed mother . 30 . Women child bear potential without satisfactory contraception , i.e . hormonal contraceptive least 14 day trial enrolment , IUD , double barrier ( woman child bear age must counsel use adequate contraception ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>